Cyclerion Therapeutics, Inc. (CYCN)

US — Healthcare Sector
Peers: TCRT  XTLB  PLRZ  QNRX  KTTA  RADX  VYNE  NBY  ADXN  AIM 

Automate Your Wheel Strategy on CYCN

With Tiblio's Option Bot, you can configure your own wheel strategy including CYCN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript
CYCN
Published: January 06, 2026 by: Seeking Alpha
Sentiment: Neutral

Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript

Read More
image for news Cyclerion Therapeutics, Inc. (CYCN) Discusses Medsteer Development Collaboration and Updates on Phase 2 Proof-of-Concept Study in Treatment-Resistant Depression Prepared Remarks Transcript
Cyclerion Therapeutics, Inc. - Pre Recorded Special Call
CYCN
Published: September 24, 2025 by: Seeking Alpha
Sentiment: Neutral

Cyclerion Therapeutics, Inc. - Pre Recorded Special Call Company Participants Regina Graul - CEO, President & Director Presentation Regina Graul CEO, President & Director Good morning, everyone. Yesterday, we announced Cyclerion's transformational relaunch as a neuropsychiatric company, supported by an MIT licensing agreement that secures foundational intellectual property.

Read More
image for news Cyclerion Therapeutics, Inc. - Pre Recorded Special Call

About Cyclerion Therapeutics, Inc. (CYCN)

  • IPO Date 2019-03-18
  • Website https://www.cyclerion.com
  • Industry Biotechnology
  • CEO Regina Graul
  • Employees 1
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.